Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neuroblastoma 8Head and Neck Neoplasms 2Ganglioneuroblastoma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Astrocytoma 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Uterine Cervical Diseases 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Oligodendroglioma 1Medulloblastoma 1Lung Neoplasms 1Kidney Neoplasms 1HIV Infections 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Acquired Immunodeficiency Syndrome 1AIDS-Related Complex 1

Interventions

Tamoxifen 2pegfilgrastim 1exemestane 1abemaciclib 1Tretinoin 1Tocopherols 1Standard of Care 1Mifepristone 1Letrozole 1Isotretinoin 1Dexmedetomidine 1Cannabidiol 1Bupivacaine 1Anastrozole 1Alitretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Breast Cancer Female × Isotretinoin × Clear all
NCT05016349 2021-08-23

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Kafrelsheikh University

Phase 3 Unknown
160 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡